Annual FCF
-$62.84 M
+$42.53 M+40.36%
31 December 2023
Summary:
Monte Rosa Therapeutics annual free cash flow is currently -$62.84 million, with the most recent change of +$42.53 million (+40.36%) on 31 December 2023. During the last 3 years, it has fallen by -$36.40 million (-137.66%). GLUE annual FCF is now -731.48% below its all-time high of -$7.56 million, reached on 31 December 2019.GLUE Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$21.39 M
+$8.40 M+28.18%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly free cash flow is currently -$21.39 million, with the most recent change of +$8.40 million (+28.18%) on 30 September 2024. Over the past year, it has increased by +$4.97 million (+18.86%). GLUE quarterly FCF is now -176.55% below its all-time high of $27.95 million, reached on 31 December 2023.GLUE Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$62.79 M
+$4.97 M+7.34%
30 September 2024
Summary:
Monte Rosa Therapeutics TTM free cash flow is currently -$62.79 million, with the most recent change of +$4.97 million (+7.34%) on 30 September 2024. Over the past year, it has increased by +$59.23 million (+48.54%). GLUE TTM FCF is now -1752.64% below its all-time high of -$3.39 million, reached on 31 March 2020.GLUE TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +40.4% | +18.9% | +48.5% |
| 3 y3 years | -137.7% | -9.4% | -1.9% |
| 5 y5 years | - | - | - |
GLUE Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -137.7% | +40.4% | -176.6% | +45.9% | -1.9% | +48.5% |
| 5 y | 5 years | -731.5% | +40.4% | -176.6% | +45.9% | -1752.6% | +48.5% |
| alltime | all time | -731.5% | +40.4% | -176.6% | +45.9% | -1752.6% | +48.5% |
Monte Rosa Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$21.39 M(-28.2%) | -$62.79 M(-7.3%) |
| June 2024 | - | -$29.79 M(-24.7%) | -$67.76 M(-2.9%) |
| Mar 2024 | - | -$39.55 M(-241.5%) | -$69.81 M(+11.1%) |
| Dec 2023 | -$62.84 M(-40.4%) | $27.95 M(-206.0%) | -$62.84 M(-48.5%) |
| Sept 2023 | - | -$26.36 M(-17.2%) | -$122.02 M(+3.7%) |
| June 2023 | - | -$31.84 M(-2.3%) | -$117.66 M(+8.1%) |
| Mar 2023 | - | -$32.59 M(+4.3%) | -$108.87 M(+3.3%) |
| Dec 2022 | -$105.38 M | -$31.23 M(+42.0%) | -$105.38 M(+15.3%) |
| Sept 2022 | - | -$22.00 M(-4.6%) | -$91.38 M(+2.8%) |
| June 2022 | - | -$23.05 M(-20.8%) | -$88.92 M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$29.09 M(+68.8%) | -$82.15 M(+18.9%) |
| Dec 2021 | -$69.09 M(+161.3%) | -$17.23 M(-11.9%) | -$69.09 M(+12.1%) |
| Sept 2021 | - | -$19.55 M(+20.1%) | -$61.62 M(+23.5%) |
| June 2021 | - | -$16.28 M(+1.6%) | -$49.90 M(+27.7%) |
| Mar 2021 | - | -$16.03 M(+64.3%) | -$39.09 M(+47.8%) |
| Dec 2020 | -$26.44 M(+249.9%) | -$9.76 M(+24.8%) | -$26.44 M(+58.5%) |
| Sept 2020 | - | -$7.82 M(+42.9%) | -$16.68 M(+88.3%) |
| June 2020 | - | -$5.47 M(+61.5%) | -$8.86 M(+161.5%) |
| Mar 2020 | - | -$3.39 M | -$3.39 M |
| Dec 2019 | -$7.56 M | - | - |
FAQ
- What is Monte Rosa Therapeutics annual free cash flow?
- What is the all time high annual FCF for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual FCF year-on-year change?
- What is Monte Rosa Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly FCF year-on-year change?
- What is Monte Rosa Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics TTM FCF year-on-year change?
What is Monte Rosa Therapeutics annual free cash flow?
The current annual FCF of GLUE is -$62.84 M
What is the all time high annual FCF for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual free cash flow is -$7.56 M
What is Monte Rosa Therapeutics annual FCF year-on-year change?
Over the past year, GLUE annual free cash flow has changed by +$42.53 M (+40.36%)
What is Monte Rosa Therapeutics quarterly free cash flow?
The current quarterly FCF of GLUE is -$21.39 M
What is the all time high quarterly FCF for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly free cash flow is $27.95 M
What is Monte Rosa Therapeutics quarterly FCF year-on-year change?
Over the past year, GLUE quarterly free cash flow has changed by +$4.97 M (+18.86%)
What is Monte Rosa Therapeutics TTM free cash flow?
The current TTM FCF of GLUE is -$62.79 M
What is the all time high TTM FCF for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high TTM free cash flow is -$3.39 M
What is Monte Rosa Therapeutics TTM FCF year-on-year change?
Over the past year, GLUE TTM free cash flow has changed by +$59.23 M (+48.54%)